Capital discipline in biotech: Building enduring companies when margins are tight
After years of constrained capital markets, biotech companies are operating in an environment where even late-stage programmes struggle to secure funding. Today’s reality is unforgiving: even when advancing a Phase 3 programme towards approval may fail to attract capital, and despite appearing de-risked, the probability of a successful Phase 3 trial outcome can still hover around 50%, depending on the disease indication.
In this environment, strong science is no longer enough. Many companies fail not because their underlying technology lacks promise, but because they misalign capital, execution, and development strategy – and only recognise the consequences when it is too late to recover.
Over the course of my career, I have seen that the companies that endure are not defined by how advanced their programmes appear, but by how effectively they translate capital into progress. That comes down to three things: the strength of the science, the quality of execution, and the ability to deliver on milestones as planned.
Capital discipline as an operating philosophy
Capital discipline is often misunderstood as simply spending less. In reality, it is an operating philosophy that aligns funding, timelines, and execution around clearly defined value creation points.
In biotech, value is created at discrete moments – when data resolves uncertainty. Until then, risk remains. Every dollar deployed should move a programme towards a meaningful data readout or decision point that advances its ability to attract further capital. Without that alignment, programmes are not just underfunded; they are often unfundable.
Maintaining this discipline requires more than a well-constructed budget. It demands a precise understanding of what it will actually take to execute. Early-stage companies routinely underestimate both costs and timelines, while overestimating how accessible capital will be when they need it. Even a well-designed study can miss milestones if execution is not grounded in operational reality.
Budgets must therefore be both credible and resilient – credible enough to secure funding, and realistic enough to absorb delays, enrolment variability, and the inevitable friction of clinical development. This level of rigour is not achieved through periodic review; it requires continuous oversight and a willingness to challenge assumptions before they become problems.
Designing development around fundable milestones
Clinical development is inherently uncertain, but funding is not. Investors respond to progress they can evaluate, which makes clinical inflection points the primary drivers of value creation.
A common mistake sponsors make is designing studies purely from a scientific perspective, without fully accounting for what it will take to fund and complete them. Larger, more comprehensive trials may generate stronger data, but if they require capital that cannot realistically be secured, they introduce risk that extends beyond science.
Disciplined organisations approach study design with both scientific and financial endpoints in mind. The question is not only what data would be ideal, but what data is necessary to reach the next value-defining milestone – and what it will cost to get there. Understanding the minimum capital required to achieve that milestone is foundational to building a credible development plan.
When timelines slip or enrolment assumptions prove overly optimistic, companies are often forced into unplanned fundraising at weak points. At that stage, even strong programmes can lose momentum, eroding both credibility and negotiating leverage.
Prioritisation under constraint
In capital-constrained environments, prioritisation becomes a strategic necessity, rather than a portfolio preference. The key question is not which programmes are most scientifically interesting, but which are most likely to create value within the resources available.
This requires a clear-eyed evaluation of each programme’s path forward. How much capital is required to reach the next meaningful milestone? How quickly can that milestone be achieved? How compelling will the resulting data be to investors or potential partners? These considerations must be weighed alongside competitive dynamics, unmet need, and the underlying risk profile of the programme.
Programmes that require less capital to generate meaningful data – and do so on shorter timelines – often provide more viable paths to value creation in constrained markets. At the same time, leaders must recognise that not every programme can advance at the same pace. Attempting to do too much at once is one of the fastest ways to dilute both capital and focus.
Partnerships and the discipline to let go
Partnerships and non-dilutive funding are important components of a broader capital strategy, but they must be approached with the same discipline as internal investments.
In challenging markets, partnerships can extend runway and accelerate progress. However, they also require difficult decisions about ownership and control. Founders and executives are often deeply invested in their programmes, which can make it difficult to relinquish value in the short term.
The reality is that an underfunded programme that sits idle creates no value. Advancing a therapy – whether independently or through partnership – should remain the priority. In many cases, accepting a smaller share of a successful outcome is preferable to retaining full ownership of a programme that never reaches patients.
Non-dilutive funding sources, including grants and contracts, can also play a role, though they are often slower-moving and subject to shifting external priorities. While valuable, they should be viewed as complementary to – rather than a replacement for – a broader financing strategy.
Why rare disease demands greater discipline
These challenges are magnified in rare disease development, where execution risk is inherently higher. Smaller patient populations, complex recruitment dynamics, and limited precedent for trial design all increase the likelihood of delays and cost overruns.
Success in this context depends on a deep understanding of the disease and patient population from the outset. This includes knowing where patients are located, estimating realistic enrolment rates, and designing studies that reflect how trials will actually be executed across sites. Optimistic projections may support initial planning, but disciplined organisations build their strategies around what is achievable in practice.
Rare disease programmes often require more flexibility and more rigorous upfront planning, as there is rarely a clear blueprint to follow. This makes capital discipline not just important, but essential.
Building organisations designed for endurance
Capital discipline ultimately depends on how organisations are structured and led. Lean teams can be highly effective, but only when they are supported by deep expertise and clear accountability.
In smaller biotech companies, every role carries significant weight. Execution cannot be delegated without oversight, and leadership must maintain visibility into both operational details and financial realities. This includes understanding how individual decisions, whether related to study design, vendor selection, or site activation, affect both cost and timeline.
Bringing in external expertise can strengthen this capability, particularly for first-time executives. However, outsourcing does not eliminate responsibility. Leaders must still ensure that development plans are grounded in realistic assumptions and that execution remains aligned with strategic goals.
A more demanding standard for biotech leadership
The biotech funding environment has evolved significantly over time. Where early-stage programmes once attracted capital based on promise alone, today even advanced programmes must demonstrate a clear and credible path forward.
In this context, capital discipline is no longer a differentiator; it is a prerequisite. Companies that endure are those that align scientific innovation with operational execution and financial strategy from the outset.
The challenge is not simply to advance a programme, but to do so in a way that consistently builds confidence – among investors, partners, and ultimately, patients. In a market that offers little margin for error, that alignment is what determines whether promising science translates into meaningful outcomes.
About the author
Dr Christopher J. Schaber has over 30 years of experience in the pharmaceutical and biotechnology industry. Dr Schaber has been president, CEO, and a director of Soligenix since August 2006. He was appointed Chairman of the Board on 8th October 2009. He has also served on the Board of Directors of the Biotechnology Council of New Jersey (“BioNJ”) since January 2009 and the Alliance for Biosecurity since October 2014. Dr Schaber has also been a member of the corporate councils of both the National Organization for Rare Diseases (“NORD”) and the American Society for Blood and Marrow Transplantation (“ASBMT”) since October 2009 and July 2009, respectively. Prior to joining Soligenix, Dr Schaber served from 1998 to 2006 as executive vice president and CEO of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas of commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, pre-clinical and clinical research, and medical affairs, as well as coordination of commercial launch preparation activities. Dr Schaber received his BA degree from Western Maryland College, his MSc degree in Pharmaceutics from Temple University School of Pharmacy, and his PhD degree in Pharmaceutical Sciences from the Union Graduate School.
